Guggenheim analyst Yatin Suneja downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with an $8 price target after the company agreed to be acquired by Sanofi (SNY).
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair
- Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP
- Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
- Vigil Neuroscience Inc trading halted, news pending
- Vigil Neuroscience Advances Clinical Trials and Financial Stability
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue